isotype-matched control mopc21 antibody Search Results


matched isotype controls igg1-apc  (Becton Dickinson)
90
Becton Dickinson matched isotype controls igg1-apc
Matched Isotype Controls Igg1 Apc, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/isotype-matched+control+mopc21+antibody/isotype+control+antibodies/pm37520563-110-31-35
Average 90 stars, based on 1 article reviews
matched isotype controls igg1-apc - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
control antibody  (Bio X Cell)
96
Bio X Cell control antibody
Control Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/isotype-matched+control+mopc21+antibody/InVivoPlus+mouse+IgG1+isotype+control%2C+unknown+specificity/pmc04013682-156-18-21
Average 96 stars, based on 1 article reviews
control antibody - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
control mab mopc 21  (Boston BioProducts)
95
Boston BioProducts control mab mopc 21
Control Mab Mopc 21, supplied by Boston BioProducts, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/isotype-matched+control+mopc21+antibody/Tris-Buffered+Saline/us08846667-269-26-38
Average 95 stars, based on 1 article reviews
control mab mopc 21 - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
mouse igg2a  (Bio X Cell)
95
Bio X Cell mouse igg2a
Mouse Igg2a, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/isotype-matched+control+mopc21+antibody/RecombiMAb+mouse+IgG2a+isotype+control%2C+unknown+specificity/pmc07817836-324-1-4
Average 95 stars, based on 1 article reviews
mouse igg2a - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
isotype matched control mouse igg1  (Bio X Cell)
96
Bio X Cell isotype matched control mouse igg1
PVSRIPO homes to secondary lymphatic organs after IT treatment in murine CT2A glioma and B16 melanoma and induces transient, local IFN-I responses. A, The murine system of meningeal lymphatic vessels draining to cLN. B, Viral titers in the indicated tissue homogenates/serum at days 1–3, 5 post IT inoculation in CT2A glioma [single dose; 5 × 10 7 plaque forming units (pfu; 5μL)]. The assay was carried out in three repeats with different sampling intervals; data shown are the combined results from two distinct series. C, PVSRIPO accumulation in cLN depends on hCD155 + host cells. The assay in B was repeated in wild-type mice bearing wild-type CT2A tumors vs. hCD155-tg mice bearing hCD155-tg CT2A tumors. Virus recovery from cLN at day 5 post IT PVSRIPO is shown. D, iLN location respective to (subcutaneous) B16 melanoma in mice. E, Viral titers in the indicated tissue homogenates at days 1–3 post IT inoculation in B16 melanoma [single dose; 5 × 10 8 pfu (50μL)]. B, C, E, Significance was determined by peer-wise Wilcoxon tests. F - H, Tandem repeat IT PVSRIPO (5 × 10 7 pfu each) vs. mock (vehicle) was administered in CT2A glioma to assess innate host responses in the tumor bearing hemisphere (top row; F - H ) and ipsilateral cLN (bottom row; F - H ). RT-qPCR analysis of (+)strand vRNA 24h after the 2 nd IT PVSRIPO infusion ( G ). RT-qPCR analysis of IFIT3, ISG15, and IRF7 transcripts 1–11 days after the 2 nd IT PVSRIPO infusion ( H ). The assay was carried out in three independent series with variable test intervals; data shown are aggregate results from all series. Significance was determined by two-tailed unpaired T tests ( G ) or two-tailed Mann-Whitney tests ( H ). I, Survival of mice bearing CT2A tumors treated as in F - H is diminished by CPLI of anti-IFNAR (400μg) on days 8, 14, and 19 (arrows) vs. CPLI of isotype-matched <t>IgG</t> control.
Isotype Matched Control Mouse Igg1, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/isotype-matched+control+mopc21+antibody/InVivoMAb+mouse+IgG1+isotype+control%2C+unknown+specificity/pmc12752778-54-16-23
Average 96 stars, based on 1 article reviews
isotype matched control mouse igg1 - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
antibody igg 1 -pe  (Becton Dickinson)
90
Becton Dickinson antibody igg 1 -pe
PVSRIPO homes to secondary lymphatic organs after IT treatment in murine CT2A glioma and B16 melanoma and induces transient, local IFN-I responses. A, The murine system of meningeal lymphatic vessels draining to cLN. B, Viral titers in the indicated tissue homogenates/serum at days 1–3, 5 post IT inoculation in CT2A glioma [single dose; 5 × 10 7 plaque forming units (pfu; 5μL)]. The assay was carried out in three repeats with different sampling intervals; data shown are the combined results from two distinct series. C, PVSRIPO accumulation in cLN depends on hCD155 + host cells. The assay in B was repeated in wild-type mice bearing wild-type CT2A tumors vs. hCD155-tg mice bearing hCD155-tg CT2A tumors. Virus recovery from cLN at day 5 post IT PVSRIPO is shown. D, iLN location respective to (subcutaneous) B16 melanoma in mice. E, Viral titers in the indicated tissue homogenates at days 1–3 post IT inoculation in B16 melanoma [single dose; 5 × 10 8 pfu (50μL)]. B, C, E, Significance was determined by peer-wise Wilcoxon tests. F - H, Tandem repeat IT PVSRIPO (5 × 10 7 pfu each) vs. mock (vehicle) was administered in CT2A glioma to assess innate host responses in the tumor bearing hemisphere (top row; F - H ) and ipsilateral cLN (bottom row; F - H ). RT-qPCR analysis of (+)strand vRNA 24h after the 2 nd IT PVSRIPO infusion ( G ). RT-qPCR analysis of IFIT3, ISG15, and IRF7 transcripts 1–11 days after the 2 nd IT PVSRIPO infusion ( H ). The assay was carried out in three independent series with variable test intervals; data shown are aggregate results from all series. Significance was determined by two-tailed unpaired T tests ( G ) or two-tailed Mann-Whitney tests ( H ). I, Survival of mice bearing CT2A tumors treated as in F - H is diminished by CPLI of anti-IFNAR (400μg) on days 8, 14, and 19 (arrows) vs. CPLI of isotype-matched <t>IgG</t> control.
Antibody Igg 1 Pe, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/isotype-matched+control+mopc21+antibody/hib19+antibody/pmc04534013-103-12-18
Average 90 stars, based on 1 article reviews
antibody igg 1 -pe - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
isotype-matched control mab r35-95 antibody  (Becton Dickinson)
90
Becton Dickinson isotype-matched control mab r35-95 antibody
PVSRIPO homes to secondary lymphatic organs after IT treatment in murine CT2A glioma and B16 melanoma and induces transient, local IFN-I responses. A, The murine system of meningeal lymphatic vessels draining to cLN. B, Viral titers in the indicated tissue homogenates/serum at days 1–3, 5 post IT inoculation in CT2A glioma [single dose; 5 × 10 7 plaque forming units (pfu; 5μL)]. The assay was carried out in three repeats with different sampling intervals; data shown are the combined results from two distinct series. C, PVSRIPO accumulation in cLN depends on hCD155 + host cells. The assay in B was repeated in wild-type mice bearing wild-type CT2A tumors vs. hCD155-tg mice bearing hCD155-tg CT2A tumors. Virus recovery from cLN at day 5 post IT PVSRIPO is shown. D, iLN location respective to (subcutaneous) B16 melanoma in mice. E, Viral titers in the indicated tissue homogenates at days 1–3 post IT inoculation in B16 melanoma [single dose; 5 × 10 8 pfu (50μL)]. B, C, E, Significance was determined by peer-wise Wilcoxon tests. F - H, Tandem repeat IT PVSRIPO (5 × 10 7 pfu each) vs. mock (vehicle) was administered in CT2A glioma to assess innate host responses in the tumor bearing hemisphere (top row; F - H ) and ipsilateral cLN (bottom row; F - H ). RT-qPCR analysis of (+)strand vRNA 24h after the 2 nd IT PVSRIPO infusion ( G ). RT-qPCR analysis of IFIT3, ISG15, and IRF7 transcripts 1–11 days after the 2 nd IT PVSRIPO infusion ( H ). The assay was carried out in three independent series with variable test intervals; data shown are aggregate results from all series. Significance was determined by two-tailed unpaired T tests ( G ) or two-tailed Mann-Whitney tests ( H ). I, Survival of mice bearing CT2A tumors treated as in F - H is diminished by CPLI of anti-IFNAR (400μg) on days 8, 14, and 19 (arrows) vs. CPLI of isotype-matched <t>IgG</t> control.
Isotype Matched Control Mab R35 95 Antibody, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/isotype-matched+control+mopc21+antibody/r3+34/pmc03129625-278-24-29
Average 90 stars, based on 1 article reviews
isotype-matched control mab r35-95 antibody - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
125 i-labeled nonspecific isotype-matched mouse igg clone mopc-21 antibody  (ICN Biomedicals)
90
ICN Biomedicals 125 i-labeled nonspecific isotype-matched mouse igg clone mopc-21 antibody
PVSRIPO homes to secondary lymphatic organs after IT treatment in murine CT2A glioma and B16 melanoma and induces transient, local IFN-I responses. A, The murine system of meningeal lymphatic vessels draining to cLN. B, Viral titers in the indicated tissue homogenates/serum at days 1–3, 5 post IT inoculation in CT2A glioma [single dose; 5 × 10 7 plaque forming units (pfu; 5μL)]. The assay was carried out in three repeats with different sampling intervals; data shown are the combined results from two distinct series. C, PVSRIPO accumulation in cLN depends on hCD155 + host cells. The assay in B was repeated in wild-type mice bearing wild-type CT2A tumors vs. hCD155-tg mice bearing hCD155-tg CT2A tumors. Virus recovery from cLN at day 5 post IT PVSRIPO is shown. D, iLN location respective to (subcutaneous) B16 melanoma in mice. E, Viral titers in the indicated tissue homogenates at days 1–3 post IT inoculation in B16 melanoma [single dose; 5 × 10 8 pfu (50μL)]. B, C, E, Significance was determined by peer-wise Wilcoxon tests. F - H, Tandem repeat IT PVSRIPO (5 × 10 7 pfu each) vs. mock (vehicle) was administered in CT2A glioma to assess innate host responses in the tumor bearing hemisphere (top row; F - H ) and ipsilateral cLN (bottom row; F - H ). RT-qPCR analysis of (+)strand vRNA 24h after the 2 nd IT PVSRIPO infusion ( G ). RT-qPCR analysis of IFIT3, ISG15, and IRF7 transcripts 1–11 days after the 2 nd IT PVSRIPO infusion ( H ). The assay was carried out in three independent series with variable test intervals; data shown are aggregate results from all series. Significance was determined by two-tailed unpaired T tests ( G ) or two-tailed Mann-Whitney tests ( H ). I, Survival of mice bearing CT2A tumors treated as in F - H is diminished by CPLI of anti-IFNAR (400μg) on days 8, 14, and 19 (arrows) vs. CPLI of isotype-matched <t>IgG</t> control.
125 I Labeled Nonspecific Isotype Matched Mouse Igg Clone Mopc 21 Antibody, supplied by ICN Biomedicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/isotype-matched+control+mopc21+antibody/mopc21+antibody/pmc01853449-79-24-28
Average 90 stars, based on 1 article reviews
125 i-labeled nonspecific isotype-matched mouse igg clone mopc-21 antibody - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
isotype-matched igg-pe mopc-21  (Becton Dickinson)
90
Becton Dickinson isotype-matched igg-pe mopc-21
PVSRIPO homes to secondary lymphatic organs after IT treatment in murine CT2A glioma and B16 melanoma and induces transient, local IFN-I responses. A, The murine system of meningeal lymphatic vessels draining to cLN. B, Viral titers in the indicated tissue homogenates/serum at days 1–3, 5 post IT inoculation in CT2A glioma [single dose; 5 × 10 7 plaque forming units (pfu; 5μL)]. The assay was carried out in three repeats with different sampling intervals; data shown are the combined results from two distinct series. C, PVSRIPO accumulation in cLN depends on hCD155 + host cells. The assay in B was repeated in wild-type mice bearing wild-type CT2A tumors vs. hCD155-tg mice bearing hCD155-tg CT2A tumors. Virus recovery from cLN at day 5 post IT PVSRIPO is shown. D, iLN location respective to (subcutaneous) B16 melanoma in mice. E, Viral titers in the indicated tissue homogenates at days 1–3 post IT inoculation in B16 melanoma [single dose; 5 × 10 8 pfu (50μL)]. B, C, E, Significance was determined by peer-wise Wilcoxon tests. F - H, Tandem repeat IT PVSRIPO (5 × 10 7 pfu each) vs. mock (vehicle) was administered in CT2A glioma to assess innate host responses in the tumor bearing hemisphere (top row; F - H ) and ipsilateral cLN (bottom row; F - H ). RT-qPCR analysis of (+)strand vRNA 24h after the 2 nd IT PVSRIPO infusion ( G ). RT-qPCR analysis of IFIT3, ISG15, and IRF7 transcripts 1–11 days after the 2 nd IT PVSRIPO infusion ( H ). The assay was carried out in three independent series with variable test intervals; data shown are aggregate results from all series. Significance was determined by two-tailed unpaired T tests ( G ) or two-tailed Mann-Whitney tests ( H ). I, Survival of mice bearing CT2A tumors treated as in F - H is diminished by CPLI of anti-IFNAR (400μg) on days 8, 14, and 19 (arrows) vs. CPLI of isotype-matched <t>IgG</t> control.
Isotype Matched Igg Pe Mopc 21, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/isotype-matched+control+mopc21+antibody/isotype+controls/pmc03208307-156-23-26
Average 90 stars, based on 1 article reviews
isotype-matched igg-pe mopc-21 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
desmin antibody  (NSJ Bioreagents)
99
NSJ Bioreagents desmin antibody
PVSRIPO homes to secondary lymphatic organs after IT treatment in murine CT2A glioma and B16 melanoma and induces transient, local IFN-I responses. A, The murine system of meningeal lymphatic vessels draining to cLN. B, Viral titers in the indicated tissue homogenates/serum at days 1–3, 5 post IT inoculation in CT2A glioma [single dose; 5 × 10 7 plaque forming units (pfu; 5μL)]. The assay was carried out in three repeats with different sampling intervals; data shown are the combined results from two distinct series. C, PVSRIPO accumulation in cLN depends on hCD155 + host cells. The assay in B was repeated in wild-type mice bearing wild-type CT2A tumors vs. hCD155-tg mice bearing hCD155-tg CT2A tumors. Virus recovery from cLN at day 5 post IT PVSRIPO is shown. D, iLN location respective to (subcutaneous) B16 melanoma in mice. E, Viral titers in the indicated tissue homogenates at days 1–3 post IT inoculation in B16 melanoma [single dose; 5 × 10 8 pfu (50μL)]. B, C, E, Significance was determined by peer-wise Wilcoxon tests. F - H, Tandem repeat IT PVSRIPO (5 × 10 7 pfu each) vs. mock (vehicle) was administered in CT2A glioma to assess innate host responses in the tumor bearing hemisphere (top row; F - H ) and ipsilateral cLN (bottom row; F - H ). RT-qPCR analysis of (+)strand vRNA 24h after the 2 nd IT PVSRIPO infusion ( G ). RT-qPCR analysis of IFIT3, ISG15, and IRF7 transcripts 1–11 days after the 2 nd IT PVSRIPO infusion ( H ). The assay was carried out in three independent series with variable test intervals; data shown are aggregate results from all series. Significance was determined by two-tailed unpaired T tests ( G ) or two-tailed Mann-Whitney tests ( H ). I, Survival of mice bearing CT2A tumors treated as in F - H is diminished by CPLI of anti-IFNAR (400μg) on days 8, 14, and 19 (arrows) vs. CPLI of isotype-matched <t>IgG</t> control.
Desmin Antibody, supplied by NSJ Bioreagents, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/isotype-matched+control+mopc21+antibody/Desmin+Antibody/custom%40rq5525%4010%2E1074%2Fjbc%2Em210707200
Average 99 stars, based on 1 article reviews
desmin antibody - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
prohibitin 2 antibody / phb2  (NSJ Bioreagents)
99
NSJ Bioreagents prohibitin 2 antibody / phb2
PVSRIPO homes to secondary lymphatic organs after IT treatment in murine CT2A glioma and B16 melanoma and induces transient, local IFN-I responses. A, The murine system of meningeal lymphatic vessels draining to cLN. B, Viral titers in the indicated tissue homogenates/serum at days 1–3, 5 post IT inoculation in CT2A glioma [single dose; 5 × 10 7 plaque forming units (pfu; 5μL)]. The assay was carried out in three repeats with different sampling intervals; data shown are the combined results from two distinct series. C, PVSRIPO accumulation in cLN depends on hCD155 + host cells. The assay in B was repeated in wild-type mice bearing wild-type CT2A tumors vs. hCD155-tg mice bearing hCD155-tg CT2A tumors. Virus recovery from cLN at day 5 post IT PVSRIPO is shown. D, iLN location respective to (subcutaneous) B16 melanoma in mice. E, Viral titers in the indicated tissue homogenates at days 1–3 post IT inoculation in B16 melanoma [single dose; 5 × 10 8 pfu (50μL)]. B, C, E, Significance was determined by peer-wise Wilcoxon tests. F - H, Tandem repeat IT PVSRIPO (5 × 10 7 pfu each) vs. mock (vehicle) was administered in CT2A glioma to assess innate host responses in the tumor bearing hemisphere (top row; F - H ) and ipsilateral cLN (bottom row; F - H ). RT-qPCR analysis of (+)strand vRNA 24h after the 2 nd IT PVSRIPO infusion ( G ). RT-qPCR analysis of IFIT3, ISG15, and IRF7 transcripts 1–11 days after the 2 nd IT PVSRIPO infusion ( H ). The assay was carried out in three independent series with variable test intervals; data shown are aggregate results from all series. Significance was determined by two-tailed unpaired T tests ( G ) or two-tailed Mann-Whitney tests ( H ). I, Survival of mice bearing CT2A tumors treated as in F - H is diminished by CPLI of anti-IFNAR (400μg) on days 8, 14, and 19 (arrows) vs. CPLI of isotype-matched <t>IgG</t> control.
Prohibitin 2 Antibody / Phb2, supplied by NSJ Bioreagents, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/isotype-matched+control+mopc21+antibody/Prohibitin+2+Antibody+%2F+PHB2/custom%40rq6364%4010%2E1074%2Fjbc%2Em210707200
Average 99 stars, based on 1 article reviews
prohibitin 2 antibody / phb2 - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
ddx5 antibody  (NSJ Bioreagents)
99
NSJ Bioreagents ddx5 antibody
PVSRIPO homes to secondary lymphatic organs after IT treatment in murine CT2A glioma and B16 melanoma and induces transient, local IFN-I responses. A, The murine system of meningeal lymphatic vessels draining to cLN. B, Viral titers in the indicated tissue homogenates/serum at days 1–3, 5 post IT inoculation in CT2A glioma [single dose; 5 × 10 7 plaque forming units (pfu; 5μL)]. The assay was carried out in three repeats with different sampling intervals; data shown are the combined results from two distinct series. C, PVSRIPO accumulation in cLN depends on hCD155 + host cells. The assay in B was repeated in wild-type mice bearing wild-type CT2A tumors vs. hCD155-tg mice bearing hCD155-tg CT2A tumors. Virus recovery from cLN at day 5 post IT PVSRIPO is shown. D, iLN location respective to (subcutaneous) B16 melanoma in mice. E, Viral titers in the indicated tissue homogenates at days 1–3 post IT inoculation in B16 melanoma [single dose; 5 × 10 8 pfu (50μL)]. B, C, E, Significance was determined by peer-wise Wilcoxon tests. F - H, Tandem repeat IT PVSRIPO (5 × 10 7 pfu each) vs. mock (vehicle) was administered in CT2A glioma to assess innate host responses in the tumor bearing hemisphere (top row; F - H ) and ipsilateral cLN (bottom row; F - H ). RT-qPCR analysis of (+)strand vRNA 24h after the 2 nd IT PVSRIPO infusion ( G ). RT-qPCR analysis of IFIT3, ISG15, and IRF7 transcripts 1–11 days after the 2 nd IT PVSRIPO infusion ( H ). The assay was carried out in three independent series with variable test intervals; data shown are aggregate results from all series. Significance was determined by two-tailed unpaired T tests ( G ) or two-tailed Mann-Whitney tests ( H ). I, Survival of mice bearing CT2A tumors treated as in F - H is diminished by CPLI of anti-IFNAR (400μg) on days 8, 14, and 19 (arrows) vs. CPLI of isotype-matched <t>IgG</t> control.
Ddx5 Antibody, supplied by NSJ Bioreagents, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/isotype-matched+control+mopc21+antibody/DDX5+Antibody/custom%40rq5934%4028939410
Average 99 stars, based on 1 article reviews
ddx5 antibody - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier

Image Search Results


PVSRIPO homes to secondary lymphatic organs after IT treatment in murine CT2A glioma and B16 melanoma and induces transient, local IFN-I responses. A, The murine system of meningeal lymphatic vessels draining to cLN. B, Viral titers in the indicated tissue homogenates/serum at days 1–3, 5 post IT inoculation in CT2A glioma [single dose; 5 × 10 7 plaque forming units (pfu; 5μL)]. The assay was carried out in three repeats with different sampling intervals; data shown are the combined results from two distinct series. C, PVSRIPO accumulation in cLN depends on hCD155 + host cells. The assay in B was repeated in wild-type mice bearing wild-type CT2A tumors vs. hCD155-tg mice bearing hCD155-tg CT2A tumors. Virus recovery from cLN at day 5 post IT PVSRIPO is shown. D, iLN location respective to (subcutaneous) B16 melanoma in mice. E, Viral titers in the indicated tissue homogenates at days 1–3 post IT inoculation in B16 melanoma [single dose; 5 × 10 8 pfu (50μL)]. B, C, E, Significance was determined by peer-wise Wilcoxon tests. F - H, Tandem repeat IT PVSRIPO (5 × 10 7 pfu each) vs. mock (vehicle) was administered in CT2A glioma to assess innate host responses in the tumor bearing hemisphere (top row; F - H ) and ipsilateral cLN (bottom row; F - H ). RT-qPCR analysis of (+)strand vRNA 24h after the 2 nd IT PVSRIPO infusion ( G ). RT-qPCR analysis of IFIT3, ISG15, and IRF7 transcripts 1–11 days after the 2 nd IT PVSRIPO infusion ( H ). The assay was carried out in three independent series with variable test intervals; data shown are aggregate results from all series. Significance was determined by two-tailed unpaired T tests ( G ) or two-tailed Mann-Whitney tests ( H ). I, Survival of mice bearing CT2A tumors treated as in F - H is diminished by CPLI of anti-IFNAR (400μg) on days 8, 14, and 19 (arrows) vs. CPLI of isotype-matched IgG control.

Journal: Cancer immunology research

Article Title: Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration

doi: 10.1158/2326-6066.CIR-25-0756

Figure Lengend Snippet: PVSRIPO homes to secondary lymphatic organs after IT treatment in murine CT2A glioma and B16 melanoma and induces transient, local IFN-I responses. A, The murine system of meningeal lymphatic vessels draining to cLN. B, Viral titers in the indicated tissue homogenates/serum at days 1–3, 5 post IT inoculation in CT2A glioma [single dose; 5 × 10 7 plaque forming units (pfu; 5μL)]. The assay was carried out in three repeats with different sampling intervals; data shown are the combined results from two distinct series. C, PVSRIPO accumulation in cLN depends on hCD155 + host cells. The assay in B was repeated in wild-type mice bearing wild-type CT2A tumors vs. hCD155-tg mice bearing hCD155-tg CT2A tumors. Virus recovery from cLN at day 5 post IT PVSRIPO is shown. D, iLN location respective to (subcutaneous) B16 melanoma in mice. E, Viral titers in the indicated tissue homogenates at days 1–3 post IT inoculation in B16 melanoma [single dose; 5 × 10 8 pfu (50μL)]. B, C, E, Significance was determined by peer-wise Wilcoxon tests. F - H, Tandem repeat IT PVSRIPO (5 × 10 7 pfu each) vs. mock (vehicle) was administered in CT2A glioma to assess innate host responses in the tumor bearing hemisphere (top row; F - H ) and ipsilateral cLN (bottom row; F - H ). RT-qPCR analysis of (+)strand vRNA 24h after the 2 nd IT PVSRIPO infusion ( G ). RT-qPCR analysis of IFIT3, ISG15, and IRF7 transcripts 1–11 days after the 2 nd IT PVSRIPO infusion ( H ). The assay was carried out in three independent series with variable test intervals; data shown are aggregate results from all series. Significance was determined by two-tailed unpaired T tests ( G ) or two-tailed Mann-Whitney tests ( H ). I, Survival of mice bearing CT2A tumors treated as in F - H is diminished by CPLI of anti-IFNAR (400μg) on days 8, 14, and 19 (arrows) vs. CPLI of isotype-matched IgG control.

Article Snippet: For in vivo IFNα/β receptor (IFNAR) blockade, 400μg of anti-mouse IFNAR1 (BioXcell; InVivoMAb #BE0241, RRID:AB_2687723) or isotype-matched control mouse IgG1 with unknown specificity (BioXcell; InVivoMAb #BE0083, RRID:AB_1107784) were used for CPLI.

Techniques: Sampling, Virus, Quantitative RT-PCR, Two Tailed Test, MANN-WHITNEY, Control